These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 10903774)
1. Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice. Drobyski WR; Vodanovic-Jankovic S; Klein J J Immunol; 2000 Aug; 165(3):1634-40. PubMed ID: 10903774 [TBL] [Abstract][Full Text] [Related]
2. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Drobyski WR; Majewski D; Hanson G Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102 [TBL] [Abstract][Full Text] [Related]
3. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. Johnson BD; Becker EE; LaBelle JL; Truitt RL J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039 [TBL] [Abstract][Full Text] [Related]
4. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice. Drobyski WR; Majewski D Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343 [TBL] [Abstract][Full Text] [Related]
5. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. Drobyski WR; Majewski D; Ozker K; Hanson G J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263 [TBL] [Abstract][Full Text] [Related]
6. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015 [TBL] [Abstract][Full Text] [Related]
7. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. Drobyski WR; Majewski D Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851 [TBL] [Abstract][Full Text] [Related]
8. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens. Blazar BR; Taylor PA; Bluestone JA; Vallera DA Blood; 1996 May; 87(10):4463-72. PubMed ID: 8639809 [TBL] [Abstract][Full Text] [Related]
9. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Johnson BD; Becker EE; Truitt RL Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958 [TBL] [Abstract][Full Text] [Related]
10. Analyses of acute graft-versus-host-like reaction in [MRL/lpr----MRL/+] chimeric mice using MRL/lpr-Thy-1. 1 congenic mice. Nakagawa T; Nagata N; Hosaka N; Inaba M; Yasumizu R; Ogawa R; Ikehara S Cell Immunol; 1991 Oct; 137(1):189-99. PubMed ID: 1679378 [TBL] [Abstract][Full Text] [Related]
11. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Johnson BD; Truitt RL Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664 [TBL] [Abstract][Full Text] [Related]
12. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. Rettig MP; Ritchey JK; Prior JL; Haug JS; Piwnica-Worms D; DiPersio JF J Immunol; 2004 Sep; 173(6):3620-30. PubMed ID: 15356106 [TBL] [Abstract][Full Text] [Related]
13. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Johnson BD; Drobyski WR; Truitt RL Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480 [TBL] [Abstract][Full Text] [Related]
14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746 [TBL] [Abstract][Full Text] [Related]
15. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044 [TBL] [Abstract][Full Text] [Related]
16. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559 [TBL] [Abstract][Full Text] [Related]
17. Host-residual invariant NK T cells attenuate graft-versus-host immunity. Haraguchi K; Takahashi T; Matsumoto A; Asai T; Kanda Y; Kurokawa M; Ogawa S; Oda H; Taniguchi M; Hirai H; Chiba S J Immunol; 2005 Jul; 175(2):1320-8. PubMed ID: 16002737 [TBL] [Abstract][Full Text] [Related]
18. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Johnson BD; Truitt RL Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918 [TBL] [Abstract][Full Text] [Related]
19. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Waller EK; Ship AM; Mittelstaedt S; Murray TW; Carter R; Kakhniashvili I; Lonial S; Holden JT; Boyer MW Blood; 1999 Nov; 94(9):3222-33. PubMed ID: 10556211 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. Roback JD; Hossain MS; Lezhava L; Gorechlad JW; Alexander SA; Jaye DL; Mittelstaedt S; Talib S; Hearst JE; Hillyer CD; Waller EK J Immunol; 2003 Dec; 171(11):6023-31. PubMed ID: 14634114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]